QMS – Page 25 – Pharma.Tips

Batch documentation gaps during routine manufacturing – how to rebuild GMP maturity

Addressing Batch Documentation Gaps to Enhance GMP Maturity Batch documentation gaps can lead to significant operational risks, regulatory non-compliance, and inadequacies in pharmacovigilance. In today’s stringent pharmaceutical environment, understanding how…

Uncontrolled SOP changes during routine manufacturing – FDA/EMA inspection citation risk

“`html Managing Uncontrolled SOP Changes to Mitigate FDA/EMA Inspection Risks Uncontrolled changes to Standard Operating Procedures (SOPs) during routine manufacturing are a significant risk factor that can lead to regulatory…

Repeated GMP deviations during regulatory inspection – evidence package for inspection defense

A Practical Playbook for Addressing Repeated GMP Deviations During Regulatory Inspections In the highly regulated pharmaceutical environment, repeated Good Manufacturing Practice (GMP) deviations can significantly undermine confidence from regulatory bodies…

Inadequate GMP training during internal audit – root cause analysis inspectors expect

Addressing Inadequate GMP Training During Internal Audits: A Practical Guide Inadequate GMP training during internal audits can lead to significant compliance risks and impacts on manufacturing efficacy, quality systems, and…

Uncontrolled SOP changes during regulatory inspection – how to rebuild GMP maturity

Addressing Uncontrolled SOP Changes During Regulatory Inspections to Enhance GMP Maturity Uncontrolled Standard Operating Procedure (SOP) changes can lead to significant challenges during regulatory inspections, compromising compliance, process integrity, and…

Weak management oversight during regulatory inspection – root cause analysis inspectors expect

Understanding Weak Management Oversight During Regulatory Inspections: A Playbook for Pharmaceutical Professionals In the complex landscape of pharmaceutical manufacturing, weak management oversight can lead to significant regulatory challenges during inspections.…

Tag: QMS

Batch documentation gaps during routine manufacturing – how to rebuild GMP maturity

Uncontrolled SOP changes during routine manufacturing – FDA/EMA inspection citation risk

Repeated GMP deviations during regulatory inspection – evidence package for inspection defense

Inadequate GMP training during internal audit – root cause analysis inspectors expect

Uncontrolled SOP changes during regulatory inspection – how to rebuild GMP maturity

Weak management oversight during regulatory inspection – root cause analysis inspectors expect

Inconsistent GMP interpretation during technology transfer – CAPA framework to prevent recurrence

Repeated GMP deviations during internal audit – FDA/EMA inspection citation risk

Repeated GMP deviations during internal audit – FDA/EMA inspection citation risk

Batch documentation gaps during technology transfer – how to rebuild GMP maturity

Poor change control discipline during internal audit – CAPA framework to prevent recurrence

Batch documentation gaps during scale-up – root cause analysis inspectors expect